Virtu Financial LLC Infinity Pharmaceuticals, Inc. Transaction History

Virtu Financial LLC

$1.82 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	SELL	$0.14 - $0.24 $19,877 - $34,076	-141,984 Reduced 80.43%	34,545 $7,000
Q1 2023 May 01, 2023	BUY	$0.16 - $0.74 $17,598 - $81,394	109,992 Added 165.31%	176,529 $28,000
Q4 2022 Feb 15, 2023	BUY	$0.46 - $1.21 $30,607 - $80,509	66,537 New	66,537 $37,000
Q2 2022 Aug 09, 2022	BUY	$0.49 - $1.2 $8,151 - $19,963	16,636 New	16,636 $11,000
Q1 2022 May 17, 2022	SELL	$0.85 - $2.4 $69,968 - $197,558	-82,316 Closed	0 $0
Q4 2021 Feb 17, 2022	BUY	$1.86 - $3.36 $87,699 - $158,424	47,150 Added 134.08%	82,316 $185,000
Q3 2021 Nov 12, 2021	SELL	$1.52 - $3.82 $121,821 - $306,157	-80,146 Reduced 69.5%	35,166 $120,000
Q2 2021 Sep 17, 2021	BUY	$2.66 - $3.47 $139,192 - $181,578	52,328 Added 83.08%	115,312 $345,000
Q1 2021 May 19, 2021	BUY	$1.98 - $5.36 $124,708 - $337,594	62,984 New	62,984 $203,000
Q3 2020 Dec 11, 2020	SELL	$0.82 - $1.34 $10,072 - $16,459	-12,283 Closed	0 $0
Q2 2020 Aug 07, 2020	SELL	$0.77 - $1.13 $11,945 - $17,529	-15,513 Reduced 55.81%	12,283 $11,000
Q4 2019 Feb 04, 2020	BUY	$0.88 - $1.29 $24,460 - $35,856	27,796 New	27,796 $27,000
Q2 2019 Aug 13, 2019	SELL	$1.43 - $1.87 $15,431 - $20,179	-10,791 Closed	0 $0
Q1 2019 Apr 12, 2019	SELL	$1.18 - $1.91 $19,959 - $32,307	-16,915 Reduced 61.05%	10,791 $20,000
Q4 2018 Jan 16, 2019	SELL	$1.01 - $2.78 $43,579 - $119,951	-43,148 Reduced 60.9%	27,706 $33,000
Q1 2018 May 14, 2018	BUY	$1.8 - $2.74 $127,537 - $194,139	70,854 New	70,854 $149,000
Q4 2017 Feb 09, 2018	SELL	$1.22 - $3.73 $12,613 - $38,564	-10,339 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$0.94 - $1.35 $9,718 - $13,957	10,339	10,339 $0

Others Institutions Holding INFI

# of Institutions

Shares Held

1.26M

Call Options Held

Put Options Held

View Full List

About INFINITY PHARMACEUTICALS, INC.

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

More about INFI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.

Account